These drugs are well-known peroxisome proliferator-activated receptor alpha (PPARα) agonists, and they have been increasingly nominated as promising drugs for various ischemic retinopathies with diabetes or hyperlipidemia [68,69]. The gene discussed is PPARA; the disease is hyperlipidemia.